Archimedes Pharma

Archimedes Pharma, a specialty pharmaceutical company, was established in 2004 by Richard de Souza. The company focuses on the development and commercialization of products aimed at underserved patient needs in niche areas, including neurology, pain management, and critical care. A significant milestone in its history was the acquisition by Kyowa Hakko Kirin Co., Ltd. in 2014, a move that integrated Archimedes into a larger global pharmaceutical entity.

The company's core business revolves around identifying, developing, and bringing to market pharmaceutical products for specialist prescribers. Its portfolio included products like PecFent®, a fentanyl nasal spray for breakthrough cancer pain, and Gliadel® Wafer, a treatment for high-grade glioma. This strategy targets specific medical conditions where existing treatments are inadequate, thereby serving a highly specialized segment of the healthcare market. The business model is based on acquiring, in-licensing, or developing drug candidates and then leveraging its specialized sales and marketing infrastructure to commercialize them across Europe and the United States.

Prior to its acquisition, Archimedes Pharma operated as an independent entity, building a reputation for its ability to manage the full lifecycle of a specialty pharmaceutical product, from clinical development through to market access and sales. The company's acquisition by Kyowa Hakko Kirin marked a strategic exit and the integration of its assets and expertise into a global organization, continuing its mission under a new corporate structure.

Keywords: specialty pharma, neurology, pain management, critical care, oncology, drug development, pharmaceutical commercialization, cancer pain, nasal spray, Gliadel Wafer